Caris Life Sciences (NASDAQ:CAI) Given New $22.00 Price Target at Canaccord Genuity Group

Caris Life Sciences (NASDAQ:CAI) had its target price cut by Canaccord Genuity Group from $30.00 to $22.00 in a research note released on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. BTIG Research decreased their price target on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Evercore set a $38.00 price objective on shares of Caris Life Sciences in a research note on Monday, January 5th. Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Finally, Robert W. Baird increased their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $31.50.

Caris Life Sciences Trading Up 2.6%

Shares of CAI stock opened at $18.15 on Friday. Caris Life Sciences has a 12 month low of $17.15 and a 12 month high of $42.50. The company has a market cap of $5.13 billion and a P/E ratio of -100.83. The stock has a 50 day moving average price of $22.67. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35.

Caris Life Sciences (NASDAQ:CAI) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. The business’s revenue for the quarter was up 125.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.73) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Global Retirement Partners LLC lifted its holdings in shares of Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares during the period. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the 4th quarter worth about $31,000. MetLife Investment Management LLC increased its position in shares of Caris Life Sciences by 84.0% during the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after purchasing an additional 755 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Caris Life Sciences during the 4th quarter worth about $67,000. Finally, Federated Hermes Inc. bought a new position in Caris Life Sciences during the 4th quarter valued at about $81,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.